Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
复制标题
米托蒽醌作为单药和联合化疗治疗难治性急性白血病。
作者：
P. Paciucci;J. Cuttner;J. Holland
共47例复发或原发难治性白血病患者接受米托蒽醌单药治疗或与硫酸长春新碱和泼尼松或阿糖胞苷联合治疗。合格的患者包括肾功能和肝功能正常、左心室射血分数正常和既往接受过治疗的患者。当米托蒽醌单独给予每日一次5倍的时间表，5 12例急性淋巴细胞白血病患者达到完全缓解，这些患者中有4例难治性再诱导和1诱导化疗与蒽环类药物的治疗。其中4例患者出现疾病进展，3例在诱导期间死亡。在12例急性髓细胞白血病患者中，1例完全缓解，1例部分缓解，8例疾病进展，2例在诱导期间死亡。米托蒽醌也被发现是积极的两名患者在急变的慢性粒细胞白血病与反应在一名患者持续17周。米托蒽醌与硫酸长春新碱和泼尼松的组合导致9例急性淋巴细胞白血病患者中的4例和4例Tdt阳性慢性髓细胞白血病急变患者中的1例完全缓解。其中3例患者在接受含蒽环类药物治疗后未出现既往缓解。部分缓解发生在两个急性淋巴细胞白血病患者和Tdt阳性慢性髓细胞白血病患者之一。后一组患者中有2例在诱导期死亡。米托蒽醌和阿糖胞苷治疗导致2例急性髓细胞白血病患者完全缓解，1例部分缓解; 2例患者病情进展，1例在诱导期死亡。1例Tdt阴性的慢性粒细胞白血病患者经2个疗程治疗后无反应。1例急性白血病患者在骨髓纤维化过程中诱导死亡。所有达到完全缓解的患者均存活，并已完全缓解2至12个月。副作用包括轻度恶心和呕吐，9/13例接受米托蒽醌-硫酸长春新碱-泼尼松联合治疗的患者，3/8例接受米托蒽醌-阿糖胞苷联合治疗的患者。联合治疗的其他副作用包括药物诱导的口腔粘膜炎（程度低于单独使用米托蒽醌），短暂的肝脏异常和感染性并发症，如败血症，上消化道念珠菌定植和软组织蜂窝织炎，在少数患者中。（400字处截断摘要）
A total of 47 patients with relapsed or primarily refractory leukemia were treated with mitoxantrone alone or in combination with vincristine sulfate and prednisone or cytarabine. Eligible patients included those with adequate renal and hepatic function, normal left ventricular ejection fraction, and those who had received previous treatment. When mitoxantrone was given alone in a once daily times five schedule, 5 of 12 acute lymphoblastic leukemia patients achieved complete remission; 4 of these patients had been refractory to reinduction and 1 to induction chemotherapy with anthracycline-containing treatments. Four of these patients had progressive disease, and three died during induction. Of 12 patients with acute myeloid leukemia, 1 had a complete remission, 1 had a partial remission, 8 had progressive disease, and 2 died during induction. Mitoxantrone was also found to be active in two patients in the blastic transformation of chronic myeloid leukemia with a response in one patient lasting 17 weeks. Combinations of mitoxantrone with vincristine sulfate and prednisone resulted in complete remission in four of nine acute lymphoblastic leukemia patients and one of four patients with Tdt-positive chronic myeloid leukemia in blast crisis. Three of these patients had not experienced a prior remission following anthracycline-containing treatments. Partial remission occurred in two of the acute lymphoblastic leukemia patients and one of the Tdt-positive chronic myeloid leukemia patients. Two of this latter group of patients died in induction. Treatment with mitoxantrone and cytarabine resulted in two acute myeloid leukemia patients achieving complete remission and one a partial remission; two patients had progressive disease, and one died in induction. No response was seen in a patient with Tdt-negative chronic myeloid leukemia after two courses of treatment. One patient with acute leukemia in the course of myelofibrosis died in induction. All the patients achieving complete remission are alive and have been in complete remission from 2 to 12 months. Side effects included mild nausea and vomiting in 9 of 13 patients treated with the mitoxantrone-vincristine sulfate-prednisone combination, and in 3 of 8 patients treated with the mitoxantrone-cytarabine combination. Other side effects of the combination treatments include drug-induced oral mucositis (of a lesser degree than with mitoxantrone alone), transient hepatic abnormalities, and infectious complications, such as sepsis, Candida sp colonization of the upper digestive tract, and soft tissue cellulitis, in a few patients.(ABSTRACT TRUNCATED AT 400 WORDS)
采用高压液相色谱法灵敏、特异地测定新型蒽环类类似物 4-表多柔比星及其代谢物。
DOI：
--
发表时间：
1984
期刊：
Drug metabolism and disposition: the biological fate of chemicals
影响因子：
--
作者：
Deesen,PE;Leyland-Jones,B
通讯作者：
Leyland-Jones,B
柔红霉素治疗成人急性淋巴细胞白血病的疗效：癌症和白血病 B 组的前瞻性随机试验。
影响因子：
20.3
作者：
Gottlieb,AJ;Weinberg,V;Ellison,RR;Henderson,ES;Terebelo,H;Rafla,S;Cuttner,J;Silver,RT;Carey,RW;Levy,RN
通讯作者：
Levy,RN